Akebia Therapeutics, Inc. (AKBA)

Market Cap	251.17M -62.3%
Revenue (ttm)	232.40M +25.7%
Net Income	-20.51M
EPS	-0.08
Shares Out	268.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,018,198
Open	1.0100
Previous Close	1.0200
Day's Range	0.9102 - 1.0190
52-Week Range	0.8750 - 4.0790
Beta	0.35
Analysts	Strong Buy
Price Target	4.20 (+348.57%)
Earnings Date	May 7, 2026

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 194
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA
• Website: https://www.akebia.com

Financial Performance

In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price target is $4.2, which is an increase of 348.57% from the latest price.

Price Target

$4.2

(348.57% upside)

Analyst Consensus: Strong Buy